NCT03823339 - A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin degludec/liraglutide

Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.

Trial Locations (3)

4184

Novo Nordisk Investigational Site, Ajman

Unknown

Novo Nordisk Investigational Site, Abu Dhabi

Novo Nordisk Investigational Site, Dubai